EpiAxis Therapeutics
Latest round
- Series A
Last raised
- Apr 2019
Total raised
- $1.7M
Investors
- 2
About EpiAxis Therapeutics
EpiAxis Therapeutics Pty Ltd specializes in epigenetic research and therapies, with its headquarters located in Canberra, Australia. The company was founded by CEO Jeremy Chrisp, who has a background in advancing biotech initiatives.EpiAxis Therapeutics specializes in innovative solutions in the field of epigenetics, particularly targeting cancer treatment and research. Their core offerings revolve around proprietary therapies and diagnostic tools designed to modify epigenetic markers, thereby influencing gene expression and cancer progression. These products aim to address the urgent need for more effective cancer treatments by providing personalized medicine approaches, which cater to the unique genetic makeup of individual patients. Their client base primarily includes research institutions, hospitals, and biotechnology firms engaged in cancer research and treatment across various geographical markets, including North America, Europe, and select regions in Asia.EpiAxis Therapeutics generates revenue through a combination of strategic partnerships, B2B collaborations, and direct service offerings for clinical trials. The company’s revenue structure involves subscription-based models for access to their proprietary software and diagnostic tools, as well as transactional agreements for their therapeutic products, which may include licensing arrangements with pharmaceutical companies. Specific revenue streams may be derived from collaborations with research institutions for joint studies or clinical trials that leverage their epigenetic technologies. The company is focused on launching several new products aimed at enhancing treatment outcomes for cancer patients, with specific timelines to be announced as development progresses. EpiAxis is targeting expansion into additional markets across Europe and Asia by 2023, aiming to establish collaborations with oncologists and research institutions in these regions to facilitate the adoption of their innovative solutions.
Who invested in EpiAxis Therapeutics
2 investors across 2 rounds
See all investors in EpiAxis Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EpiAxis Therapeutics
Who invested in EpiAxis Therapeutics?
EpiAxis Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EpiAxis Therapeutics raised?
EpiAxis Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did EpiAxis Therapeutics last raise money?
EpiAxis Therapeutics's most recent round on record is a Series A, in Apr 2019.
What does EpiAxis Therapeutics do?
EpiAxis Therapeutics Pty Ltd specializes in epigenetic research and therapies, with its headquarters located in Canberra, Australia.
Where is EpiAxis Therapeutics headquartered?
EpiAxis Therapeutics is headquartered in Canberra, Australia.
Which VCs invest in companies like EpiAxis Therapeutics?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Immutable Ventures back healthcare specialists companies at EpiAxis Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series A
Raising like EpiAxis Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.